Ligand Pharmaceuticals Incorporated
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 241.54M | 196.25M | 131.31M | 167.13M | 268.09M | 60.4% | |
| Cost of Revenue | (62.18M) | (52.83M) | (35.05M) | (11.07M) | (6.59M) | -40.5% | |
Gross Profit | 179.37M | 143.42M | 96.27M | 156.06M | 261.50M | 67.6% | |
| Operating Expenses | |||||||
| Research & Development | (32.10M) | (36.08M) | (24.54M) | (21.43M) | (81.18M) | 278.9% | |
| Selling, General & Administrative | (46.79M) | (70.06M) | (52.79M) | (78.65M) | (92.45M) | 17.5% | |
| General & Administrative | (46.79M) | (70.06M) | (52.79M) | (78.65M) | (92.45M) | 17.5% | |
| Depreciation & Amortization | (50.95M) | (43.39M) | (36.52M) | (35.24M) | (33.77M) | -4.2% | |
Operating Income (EBIT) | 103.85M | 3.04M | 11.94M | -22.61M | 47.20M | -308.8% | |
| Non-Operating Items | |||||||
| Interest Income | 886.00K | 2.05M | 7.71M | 8.05M | 13.66M | 69.6% | |
| Interest Expense | (19.62M) | (1.80M) | (656.00K) | (3.04M) | (4.71M) | 55.3% | |
| Other Income/Expenses (Net) | -31.65M | 32.97M | 51.72M | 25.12M | 111.76M | 344.8% | |
Income Before Tax | 72.20M | 36.01M | 63.66M | 2.52M | 158.96M | 6212.9% | |
| Income Tax Expense | (4.15M) | (41.23M) | (9.84M) | (6.55M) | (34.51M) | 426.8% | |
Net Income | 57.14M | -33.36M | 52.15M | -4.03M | 124.45M | -3186.6% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $3 | $-2 | $3 | $-0 | $6 | -3027.3% | |
| Weighted Avg Shares Outstanding | 16.63M | 16.87M | 17.30M | 18.29M | 19.34M | 5.7% | |
| Weighted Avg Shares Outstanding (Diluted) | 17.25M | 16.87M | 17.76M | 18.29M | 20.29M | 11.0% | |
EBITDA | 142.77M | 81.20M | 100.84M | 40.79M | 192.74M | 372.5% |
Explore LGND
LGND in the Healthcare
Mid Cap